Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02602145 · ClinicalTrials.gov registry record
Optimal Stent Selection for the Femoropopliteal Artery
A clinical trial, sponsored by University of Nebraska.
- Terminated
- Registry status
- 5
- Enrollment target
NCT02602145: Clinical Trial study, sponsored by University of Nebraska.
NCT02602145 is a clinical trial that was terminated before completion, run by University of Nebraska. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02602145 was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
Angioplasty and stenting for atherosclerotic occlusive disease in the arteries supplying the legs (Peripheral Arterial Disease, PAD) is the most common endovascular procedure outside of the heart, but carries the highest rate of reconstruction failure. The underlying reasons for these poor results are not completely clear, but the main arterial segment within the leg, the femoropopliteal artery, appears to be significantly different from other peripheral arteries because the Superficial Femoral Artery (SFA) and Popliteal Artery (PA) that comprise the femoropopliteal artery (FPA) segment, undergo large deformations during flexion of the limb. We propose to build mathematical models of human FPAs repaired with several frequently used PAD stents. These mathematical models would be able to assess the mechanical stress in the stented SFA and PA associated with limb flexion and predict disease recurrence for arteries with different patient and lesion characteristics. Results of model predictions will be validated in patients with PAD stents who have received these stents as part of their standard of care.
Primary Outcome
Radius of the femoropopliteal artery lumen will be measured using follow-up CTA to assess narrowing of the artery after stent implantation.
Interventions
- OTHER follow-up CTA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-09-02 |
| Est. Completion | 2021-04-16 |
Why NCT02602145 stopped before completion
NCT02602145 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which follow-up CTA is the first listed.
NCT02602145 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02602145 about?
NCT02602145 is a clinical study titled "Optimal Stent Selection for the Femoropopliteal Artery". Angioplasty and stenting for atherosclerotic occlusive disease in the arteries supplying the legs (Peripheral Arterial Disease, PAD) is the most common endovascular procedure outside of the heart, but carries the highest rate of reconstruction failure. The underlying reasons for these poor results a...
What is the current status of trial NCT02602145?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2014-09-02. Estimated completion is 2021-04-16.
What interventions are being tested in trial NCT02602145?
The interventions under investigation include: follow-up CTA (OTHER).
Who is sponsoring clinical trial NCT02602145?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI